ME02425B - Peptidi koji imaju farmakološku aktivnost za liječenje poremećaja povezanih sa izmijenjenom migracijom ćelija, kao što je kancer - Google Patents
Peptidi koji imaju farmakološku aktivnost za liječenje poremećaja povezanih sa izmijenjenom migracijom ćelija, kao što je kancerInfo
- Publication number
- ME02425B ME02425B MEP-2016-16A MEP1616A ME02425B ME 02425 B ME02425 B ME 02425B ME P1616 A MEP1616 A ME P1616A ME 02425 B ME02425 B ME 02425B
- Authority
- ME
- Montenegro
- Prior art keywords
- arg
- ace
- aib
- phe
- alkylated
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract 6
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract 5
- 201000011510 cancer Diseases 0.000 title claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 230000012292 cell migration Effects 0.000 title 1
- 230000000144 pharmacologic effect Effects 0.000 title 1
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract 11
- 125000002252 acyl group Chemical group 0.000 claims abstract 2
- 150000001875 compounds Chemical class 0.000 claims 5
- CQZWLVDDIOZTJI-RYUDHWBXSA-N (2s)-2-amino-n-[(2s)-1-amino-1-oxo-3-phenylpropan-2-yl]-5-(diaminomethylideneamino)pentanamide Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@H](C(N)=O)CC1=CC=CC=C1 CQZWLVDDIOZTJI-RYUDHWBXSA-N 0.000 claims 4
- OBSIQMZKFXFYLV-QMMMGPOBSA-N L-phenylalanine amide Chemical compound NC(=O)[C@@H](N)CC1=CC=CC=C1 OBSIQMZKFXFYLV-QMMMGPOBSA-N 0.000 claims 4
- 108010083298 arginylphenylalaninamide Proteins 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- PQBHGSGQZSOLIR-RYUDHWBXSA-N Arg-Phe Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PQBHGSGQZSOLIR-RYUDHWBXSA-N 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000029433 Herpesviridae infectious disease Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 208000001344 Macular Edema Diseases 0.000 claims 1
- 206010025415 Macular oedema Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 230000002152 alkylating effect Effects 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine group Chemical group NC(=N)N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims 1
- 230000009545 invasion Effects 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 201000010230 macular retinal edema Diseases 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 1
- 230000002207 retinal effect Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 abstract 7
- 229910052799 carbon Inorganic materials 0.000 abstract 3
- 230000002209 hydrophobic effect Effects 0.000 abstract 3
- 125000006165 cyclic alkyl group Chemical group 0.000 abstract 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 1
- 239000004471 Glycine Substances 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 150000001414 amino alcohols Chemical class 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 210000004899 c-terminal region Anatomy 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1019—Tetrapeptides with the first amino acid being basic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K4/00—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
- C07K4/12—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Claims (9)
1.Peptidi i njihovi funkcionalno ekvivalentni derivati, u slanom ili neslanom obliku, sa opštom formulom L1-X1- X2- X3- X4, u kojoj:L1 je H, ili acil;X1 i X3, koji su jednaki ili različiti, opciono N-alkilovani i/ili Cα-alkilovani, su izabrani iz Arg, Orn i Lys, opciono gvanidinilsani, i fenilalanina supstituisanog u mata ili para položaju sa amin ili gvanidin grupom;X2 je izabran iz Aib, Ac3c, Ac4c, Ac5c i Ac6c, opciono N-alkilovani;X4 je izabran između Phe, h-Phe, Tyr, Trp, 1-Nal, 2-Nal, h-1-Nal, h-2-Nal, Cha, Chg i Phg, opciono amidisani i/ili Cα-alkilovani.
2. Peptidi kao u zahtjevu 1, u kome acilirajući i alkilirajući ostaci sadrže 1 do 9 atoma ugljenika, amidisani C-terminalni ostatak sadrži 0 do 14 atoma ugljenika, i Cα-alkilovani ostatak sadrži 1do 9 atoma ugljenika.
3. Peptidi kao u zahtjevu 1, u kome acilisani i alkilovani ostaci sadrže 1 do 2 atoma ugljenika, i amidisani C-terminalni ostatak sadrži 0 do 5 atoma ugljenika.
4. Peptidi kao u zahtjevima 1 do 3 sa redosledom: Ace-Arg-Aib-Arg-Phe-NH2; Ace-Arg-Aib-Arg-Tyr-NH2; Ace-Arg-Aib-Arg-Trp-NH2; Ace-Arg-Aib-N(Me)Arg-Phe-NH2; Ace-Arg-Aib-N(Me)Arg-Tyr-NH2; Ace-Arg-Aib-N(Me)Arg-Trp-NH2; Ace-Arg-Ac5c-Arg-Phe-NH2; Ace-Arg-Ac5c-Arg-Tyr-NH2; Ace-Arg-Ac5c-Arg-Trp-NH2; Ace-Arg-Ac5c-N(Me)Arg-Phe-NH2; Ace-Arg-Ac5c-N(Me)Arg-Tyr-NH2; Ace-Arg-Ac5c-N(Me)Arg-Trp-NH2; Ace-Arg-Aib-Arg-Phe-OH; Ace-Arg-Aib-N(Me)Arg-Phe-OH; Ace-Arg-Ac5c-Arg-Phe-OH; Ace-Arg-Ac5c-N(Me)Arg-Tyr-OH; Ace- N(Me)Arg-Aib-Arg-Phe-NH2; Ace-N(Me)Arg-Aib-N(Me)Arg-Phe-NH2;Ace-Arg-Aib-N(Me)Arg-Phe-NH2; Ace-Arg-Aib-Arg-α(Me)Phe-NH2;; Ace-N(Me)Arg-Aib-Arg-α(Me)Phe-NH2;; Ace-N(Me)Arg-Aib-N(Me)Arg- α(Me)Phe-NH2;; Ace-Arg-Aib- N(Me)Arg-α(Me)Phe-NH2.
5. Farmaceutski pripravci koji sadrže jedno od jedinjenja utvrđeno u patentnim zahtjevima 1 do 4 u saradnji sa odgovarajućim nosačima ili pomoćnim supsatancama.
6. Upotreba jedinjenja prema patentnim zahtjevima 1 do 4, za proizvodnju lijeka za prevenciju i liječenje lokalnih i metastatskih invazija malignih tumora.
7. Upotreba jedinjenja kako su navedena u patentnim zahtjevima 1 do 4, za proizvodnju lijeka za prevenciju i liječenje vaskulopatije retine, retinopatije, makularne degeneracije i edema, i Kapošijevog sarkoma.
8. Upotreba jedinjenja kako su navedena u patentnim zahtjevima 1 do 4, za proizvodnju lijeka za prevenciju i liječenje autoimunih bolesti, reumatoidnog artritisa, psorijaze, i hroničnih granulomatoznih poremećaja.
9. Upotreba jedinjenja kako su utvrđena u patentnim zahtjevima 1 do 4, za proizvodnju lijeka za prevenciju i liječenje herpes virusne infekcije.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT001607A ITMI20061607A1 (it) | 2006-08-09 | 2006-08-09 | Peptidi con attivita farmacologica |
| PCT/EP2007/006424 WO2008017372A1 (en) | 2006-08-09 | 2007-07-19 | Peptides having pharmacological activity for treating disorders associated with altered cell migration, such as cancer |
| EP07786192A EP2049562B1 (en) | 2006-08-09 | 2007-07-19 | Peptides having pharmacological activity for treating disorders associated with altered cell migration, such as cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02425B true ME02425B (me) | 2016-09-20 |
Family
ID=38776401
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2016-16A ME02425B (me) | 2006-08-09 | 2007-07-19 | Peptidi koji imaju farmakološku aktivnost za liječenje poremećaja povezanih sa izmijenjenom migracijom ćelija, kao što je kancer |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US8354374B2 (me) |
| EP (3) | EP2049562B1 (me) |
| JP (1) | JP5384342B2 (me) |
| KR (1) | KR101464576B1 (me) |
| CN (1) | CN101501060B (me) |
| AT (1) | ATE544775T1 (me) |
| AU (1) | AU2007283150B2 (me) |
| BR (1) | BRPI0715407A2 (me) |
| CA (1) | CA2660183C (me) |
| CY (2) | CY1113941T1 (me) |
| DK (2) | DK2213680T3 (me) |
| ES (2) | ES2404052T3 (me) |
| HR (1) | HRP20130331T1 (me) |
| IL (1) | IL196929A (me) |
| IT (1) | ITMI20061607A1 (me) |
| ME (1) | ME02425B (me) |
| MX (1) | MX2009001452A (me) |
| PL (2) | PL2213680T3 (me) |
| PT (2) | PT2213680E (me) |
| RS (1) | RS52786B (me) |
| SI (2) | SI2049562T1 (me) |
| WO (1) | WO2008017372A1 (me) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104961822A (zh) | 2009-07-13 | 2015-10-07 | 西兰制药公司 | 酰化胰高血糖素类似物 |
| TW201136942A (en) | 2009-12-18 | 2011-11-01 | Idenix Pharmaceuticals Inc | 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors |
| CN104780930A (zh) * | 2011-09-30 | 2015-07-15 | 程云 | 丙型肝炎病毒免疫原性肽或其衍生物在预防或治疗关节炎中的应用 |
| EA028665B1 (ru) | 2012-05-03 | 2017-12-29 | Зилэнд Фарма А/С | Соединения - двойные агонисты gip-glp-1 и способы |
| JP6534927B2 (ja) | 2012-07-23 | 2019-06-26 | ジーランド ファーマ アクティーゼルスカブ | グルカゴン類似体 |
| TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
| CN119119233A (zh) | 2013-10-17 | 2024-12-13 | 西兰制药公司 | 酰化胰高血糖素类似物 |
| US9988429B2 (en) * | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
| CA2929459C (en) | 2013-11-06 | 2022-05-03 | Zealand Pharma A/S | Gip-glp-1 dual agonist compounds and methods |
| KR102310392B1 (ko) | 2013-11-06 | 2021-10-13 | 질랜드 파마 에이/에스 | 글루카곤-ｇｌｐ-1-ｇｉｐ 삼원 효능제 화합물 |
| KR102620911B1 (ko) | 2014-10-29 | 2024-01-05 | 질랜드 파마 에이/에스 | Gip 효능제 화합물 및 방법 |
| AU2016247499B2 (en) | 2015-04-16 | 2020-09-03 | Zealand Pharma A/S | Acylated glucagon analogue |
| ITUB20169937A1 (it) * | 2016-01-12 | 2017-07-12 | Medical And Biotechnological Services In Sigla M B S Srl | Formulazioni farmaceutiche e loro uso per il trattamento della retinite pigmentosa |
| ITUB20169928A1 (it) * | 2016-01-12 | 2017-07-12 | Medical And Biotechnological Services In Sigla M B S Srl | Formulazioni farmaceutiche per il trattamento del diabete |
| EP3231811A1 (en) | 2016-04-11 | 2017-10-18 | Istituto Nazionale Tumori Irccs "Fondazione G. Pascale" | Retro-inverso peptide inhibitors of cell migration, extracellular matrix and endothelial invasion by tumor cells |
| KR20180133463A (ko) * | 2016-04-14 | 2018-12-14 | 타오 헬스 라이프 파마 가부시키가이샤 | 아밀로스페로이드(aspd) 결합 저해 펩타이드, 및 평가 및 스크리닝 방법 |
| EP3856757A4 (en) * | 2018-09-28 | 2022-06-29 | Nutcracker Therapeutics, Inc. | Tertiary amino lipidated cationic peptides for nucleic acid delivery |
| IT202200007754A1 (it) | 2022-04-19 | 2023-10-19 | Iridea S R L | Nuovi composti con attivita’ farmacologica |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES501583A0 (es) * | 1981-04-23 | 1982-02-16 | Jorba Puigsubira Jose Ma | Un procedimiento para la preparacion de oligopeptidos lisi- na-triptofano y de sus derivados y sales fisiologicamente aprovechables |
| CA2094785A1 (en) * | 1992-05-08 | 1993-11-09 | Jean Gariepy | Metal chelating peptide |
| US20030009022A1 (en) * | 1993-03-31 | 2003-01-09 | Cadus Pharmaceutical Corporation | Methods and compositions for identifying receptor effectors |
| US6046167A (en) * | 1998-03-25 | 2000-04-04 | University Of Cincinnati | Peptide YY analogs |
| US6388054B1 (en) * | 1998-08-20 | 2002-05-14 | John M. Stewart | Anti-cancer compounds |
| JP4486187B2 (ja) | 1998-10-27 | 2010-06-23 | 武田薬品工業株式会社 | 新規ｇ蛋白質共役型レセプター蛋白質、そのｄｎａおよびそのリガンド |
| DK174549B1 (da) * | 2000-02-01 | 2003-05-26 | Raaco Internat A S | Indretning til optagelse og fastholdelse af værktøjer |
| EP1269198A2 (en) * | 2000-03-23 | 2003-01-02 | Novartis AG | Identification of mast/basophil activation inhibitors |
| WO2001075104A1 (fr) | 2000-03-30 | 2001-10-11 | Takeda Chemical Industries, Ltd. | Nouvelle proteine, adn codant pour celle-ci, et son procede de production |
| WO2002023184A1 (en) * | 2000-09-13 | 2002-03-21 | Eleanor Roosevelt Institute | Method for treatment of insulin resistance in obesity and diabetes |
| US7737256B2 (en) * | 2001-01-25 | 2010-06-15 | Fondazione Centro San Raffaele Del Monte Tabor | Antibody against uPA/uPAR |
| US6815426B2 (en) * | 2001-02-16 | 2004-11-09 | E. I. Du Pont De Nemours And Company | Angiogenesis-inhibitory tripeptides, compositions and their methods of use |
| WO2002085399A1 (fr) | 2001-04-20 | 2002-10-31 | Takeda Chemical Industries, Ltd. | Preparations contenant un peptide |
| DE60327407D1 (de) * | 2002-01-29 | 2009-06-10 | Posco Pohang | Immunmodulierende peptide |
| WO2004085455A1 (en) * | 2003-03-24 | 2004-10-07 | The University Of Hong Kong | A diagnostic assay for the human virus causing severe acute respiratory syndrome (sars) |
| JP4346650B2 (ja) | 2004-06-25 | 2009-10-21 | 武田薬品工業株式会社 | メタスチン誘導体およびその用途 |
| US8143228B2 (en) * | 2004-07-12 | 2012-03-27 | Medical Research Fund Of Tel Aviv Sourasky Medical Center | Agents capable of downregulating an MSF-A dependent HIF-1α and use thereof in cancer treatment |
| ES2469676T3 (es) * | 2006-05-25 | 2014-06-18 | Bayer Intellectual Property Gmbh | Complejos moleculares dim�ricos |
-
2006
- 2006-08-09 IT IT001607A patent/ITMI20061607A1/it unknown
-
2007
- 2007-07-19 EP EP07786192A patent/EP2049562B1/en active Active
- 2007-07-19 DK DK10156101.7T patent/DK2213680T3/da active
- 2007-07-19 EP EP10156101A patent/EP2213680B1/en not_active Not-in-force
- 2007-07-19 KR KR1020097002560A patent/KR101464576B1/ko not_active Expired - Fee Related
- 2007-07-19 DK DK07786192.0T patent/DK2049562T3/da active
- 2007-07-19 AU AU2007283150A patent/AU2007283150B2/en not_active Ceased
- 2007-07-19 BR BRPI0715407-0A patent/BRPI0715407A2/pt not_active IP Right Cessation
- 2007-07-19 WO PCT/EP2007/006424 patent/WO2008017372A1/en not_active Ceased
- 2007-07-19 PT PT101561017T patent/PT2213680E/pt unknown
- 2007-07-19 HR HRP20130331TT patent/HRP20130331T1/hr unknown
- 2007-07-19 PL PL10156101T patent/PL2213680T3/pl unknown
- 2007-07-19 US US12/376,465 patent/US8354374B2/en not_active Expired - Fee Related
- 2007-07-19 JP JP2009523170A patent/JP5384342B2/ja not_active Expired - Fee Related
- 2007-07-19 CN CN2007800292667A patent/CN101501060B/zh not_active Expired - Fee Related
- 2007-07-19 MX MX2009001452A patent/MX2009001452A/es active IP Right Grant
- 2007-07-19 ES ES07786192T patent/ES2404052T3/es active Active
- 2007-07-19 PL PL07786192T patent/PL2049562T3/pl unknown
- 2007-07-19 ME MEP-2016-16A patent/ME02425B/me unknown
- 2007-07-19 EP EP10156125A patent/EP2230245B1/en active Active
- 2007-07-19 ES ES10156101T patent/ES2406090T3/es active Active
- 2007-07-19 RS RS20130195A patent/RS52786B/sr unknown
- 2007-07-19 SI SI200731228T patent/SI2049562T1/sl unknown
- 2007-07-19 PT PT77861920T patent/PT2049562E/pt unknown
- 2007-07-19 SI SI200731220T patent/SI2213680T1/sl unknown
- 2007-07-19 AT AT10156125T patent/ATE544775T1/de active
- 2007-07-19 CA CA2660183A patent/CA2660183C/en not_active Expired - Fee Related
-
2009
- 2009-02-05 IL IL196929A patent/IL196929A/en active IP Right Grant
-
2013
- 2013-04-23 CY CY20131100329T patent/CY1113941T1/el unknown
- 2013-05-29 CY CY20131100426T patent/CY1114014T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02425B (me) | Peptidi koji imaju farmakološku aktivnost za liječenje poremećaja povezanih sa izmijenjenom migracijom ćelija, kao što je kancer | |
| BR112012011787A2 (pt) | peptídeo cíclico, composição farmacêutica, método para tratamento de uma doença, indicação, condição ou síndrome mediada por receptor de melanocortina em um mamífero humano ou não humano e método para tratamento de uma condição responsiva a mudanças na função de receptor de melanocortina em mamífero humano ou não humano | |
| RU2014143443A (ru) | Иммуномодулирующие циклические соединения | |
| JP5548866B2 (ja) | 治療効果の改善のための新規の光学的に純粋な化合物 | |
| ES2325983T3 (es) | Analogos y peptidomimeticos de gpe. | |
| NZ756128A (en) | Novel peptides and analogs for use in the treatment of oral mucositis | |
| KR101842978B1 (ko) | 에즈린-유래 펩티드 및 이의 약제학적 조성물 | |
| AU2010295996B2 (en) | Advantageous mu-opiate receptor peptide compounds | |
| US8372406B2 (en) | Antitumoral and antiviral peptides | |
| ES2536285T3 (es) | Nuevos compuestos antitumorales | |
| RU2018125290A (ru) | Фармацевтические композиции и их применение для лечения пигментного ретинита | |
| AR030222A1 (es) | Peptidos analogos de somatostatina, un procedimiento para su sintesis, composiciones que los comprenden y el uso de los mismos para la manufactura de un medicamento para el tratamiento de cancer | |
| EA200400603A1 (ru) | Новые пептиды - аналоги гормона высвобождения гормона роста человека | |
| CN104130311B (zh) | 一种抗肿瘤肽变体及其应用 | |
| CA2118253A1 (en) | Tachiquinine antagonist tricyclic compounds, preparation of same and pharmaceutical compositions containing such compounds | |
| RU2008152813A (ru) | Пептиды с антипролиферативной активностью | |
| HRP20050242A2 (en) | Synthetic peptides containing unnatural adamantane related amino acids for use as antitumour drugs | |
| Yogeswari et al. | Research Article Quantum Density Functional Theory Studies on Additive Hydration of Tuftsin Tetrapeptide | |
| EA201401291A2 (ru) | Биологически активные производные аллоферона-1 | |
| Daletos et al. | Synthesis and biological evaluation of cyclic peptides of α 4 β 1 integrin antagonists | |
| TH66935A (th) | อนุพันธ์เพพไทด์ที่มีฤทธิ์กระตุ้น par-2 และสารผสมทางยาที่ใช้อนุพันธ์เพพไทด์นั้น | |
| TH161931A (th) | เกลือเพนตะเดคาเปปไทด์แบบคงตัวชนิดใหม่, กระบวนการสำหรับการเตรียมสารนี้, การใช้สารนี้ในการผลิตสารเตรียมทางเภสัชกรรมและการใช้สารนี้ในการบำบัด | |
| HK1160778B (en) | Pharmaceutical composition comprising an analgesic peptide |